Элигард (leuprolide acetate) is a hormone therapy primarily relevant in conditions characterized by periods of heightened symptoms, specifically advanced, hormone-dependent prostate cancer. The main use is for the palliative treatment of this disease. This is commonly used across conditions presenting with acute episodes where supportive symptom management is appropriate.

As a therapeutic option, this approach supports patients during episodes of heightened discomfort by addressing symptoms related to systemic imbalance. The clinical scenarios where it is applied when appropriate include managing hormone-sensitive prostate cancer. This treatment contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

“The use of this therapy is often applied to provide support that helps ease the overall symptom burden in situations where the condition is advanced.”

Quick Fact: Relief for symptoms related to physical discomfort.

Eligibility Map: Who Can and Cannot Use Элигард (Leuprorelin acetate) — Official Regulatory Information

The following rules detail the eligibility and non-eligibility for using Элигард, strictly based on government-approved product labeling.

---

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adult men with advanced prostate cancer.

Populations for whom use is contraindicated:

• Patients with known hypersensitivity to GnRH, GnRH agonist analogs (including leuprorelin acetate), or any component of the formulation.
• Women, including those who are pregnant or who may become pregnant.
• Patients who previously underwent orchiectomy (surgical castration).

Age-related eligibility rules:

• Pediatric Use (for Prostate Cancer): Safety and effectiveness are not established in children.
• Geriatric Use (65 years): Safety and effectiveness are established for the prostate cancer indication.

Eligibility-related restrictions:

• Comorbidities: Use requires monitoring in patients with pre-existing cardiovascular diseases or diabetes due to labeled risks associated with GnRH agonists.
• Organ Impairment: Use is not established in patients with hepatic or renal impairment due to a lack of specific clinical studies.
• Spinal/Urinary Risk: Contraindicated as sole treatment for prostate cancer patients with spinal cord compression or evidence of spinal metastases.

---

Connection to the Overall Eligibility Profile

Official regulatory documents define the eligible group as primarily adult men with advanced prostate cancer. The use is strictly contraindicated in women and patients with hypersensitivity. Furthermore, patients with conditions like cardiovascular disease or diabetes must be subject to monitoring, while use is not established in those with severe liver or kidney problems due to insufficient data.

Interactions with Other Medicinal Products

No pharmacokinetic drug-drug interaction studies have been conducted for this product. However, interactions are anticipated based on the known pharmacodynamic effects of androgen deprivation therapy, which can increase certain risks when combined with other medicines or in patients with pre-existing conditions.

Potential Pharmacodynamic Interactions

Interacting Product Category	Interaction Mechanism and Constraint
Drugs that Prolong the QT Interval	Co-administration may increase the risk of QTc interval prolongation, which can lead to abnormal heart rhythms. Caution is advised, and the benefits of combined therapy should be weighed against the potential cardiac risks, particularly in patients with existing heart conditions or electrolyte abnormalities.
Drugs that Reduce Bone Mass	The therapy is associated with a risk of decreased bone mineral density. Caution is advised when used concurrently with chronic medications known to reduce bone mass, such as corticosteroids and some anticonvulsants, as this may increase the risk of osteoporosis or fractures.
Antidiabetic Medications	Treatment can be associated with hyperglycemia (high blood sugar). Patients with pre-existing diabetes may require closer monitoring of their blood glucose levels and potential adjustment of their antidiabetic therapy.
Medications Associated with Convulsions	The product has been associated with convulsions. Caution is advised when used in patients taking other medicines known to be associated with an increased risk of seizures.

These interactions are primarily related to the cumulative risk of pharmacodynamic effects—specifically cardiac rhythm changes and effects on bone and blood sugar—rather than drug metabolism issues. Consultation with a healthcare provider is necessary to review all current medications and health factors to manage these risks.

Элигард, containing leuprolide acetate, functions as a synthetic gonadotropin-releasing hormone (GnRH) receptor agonist.

Upon initial administration, the molecule binds to GnRH receptors on the anterior pituitary gland, transiently acting as a super-agonist. This initial interaction causes an acute, temporary surge in the secretion of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a transient rise in systemic testosterone concentrations—the flare effect. With continuous exposure, the constant, non-pulsatile stimulation induces the desensitization and downregulation of the pituitary GnRH receptors. This receptor loss effectively shuts down the responsiveness of the pituitary to GnRH signaling, leading to a profound and sustained suppression of LH and FSH release. The downstream consequence is a drastic reduction in the stimulation of Leydig cells in the testes, resulting in significantly decreased endogenous testosterone synthesis and subsequent circulating levels. This sustained chemical castration level of testosterone suppression modulates androgen-dependent physiological processes.

How Элигард is Used

Элигард (leuprolide acetate) is a long-acting prescription medicine administered exclusively by subcutaneous (SC) injection. Due to the required preparation steps and the specialized nature of the depot formulation, this medicine must be administered by a healthcare professional in a clinical setting.

---

Official Dosing Schedule

Usage of Элигард is defined by four fixed-dose strengths, where the chosen dose dictates the mandatory treatment frequency. The medicine is designed to provide the continuous release of leuprolide over the entire dosing interval, making daily administration unnecessary.

Dose Strength	Administration Frequency
7.5 mg	Every month
22.5 mg	Every 3 months
30 mg	Every 4 months
45 mg	Every 6 months

---

Key Administration Principles

Preparation involves a critical reconstitution process using the provided two-syringe system. It is explicitly mandated that the components must be allowed to reach room temperature prior to mixing, and the mixture must be administered within 30 minutes of reconstitution to ensure the correct formation of the long-acting depot. The injection site, typically the abdomen or upper buttocks, must be an area with adequate subcutaneous tissue and should be varied periodically to avoid localized tissue changes.

If a scheduled injection is missed, the dose should be administered as soon as possible upon realization of the omission. Subsequent doses should then be administered according to the original treatment schedule. The treatment is typically a long-term regimen and should not be discontinued without consultation.

Research evidence / Overview of studies for Элигард (Eligard)

The clinical evaluation of Элигард focuses on studies for advanced, hormone-dependent prostate cancer, with research centering on measurements related to specific hormonal levels. This summary outlines the types of research conducted, the focus of their measurements, and areas where more data is needed, according to official and scientific sources.

---

Evidence for Use in Advanced Prostate Cancer

The primary evidence base for the medicine was derived from pivotal Phase 3 clinical trials. These studies were mostly open-label, meaning both the researchers and the participants knew which treatment was being used. Research was observed in adult males with advanced prostate cancer who were candidates for hormonal treatment. The core studies explored how the medicine's profile evolved over several months of observation.

The findings describe patterns observed in the studies: specifically, that measurements of serum testosterone concentration in the observed populations commonly reached suppressed levels consistent with the castrate threshold. This measurement was used as the primary outcome for the regulatory evaluation of this class of medicine. Additionally, research has explored changes measured during the study period related to the Prostate-Specific Antigen (PSA), which is a key biomarker monitored in this condition. These studies contribute to the broader evidence landscape by providing context on short-term changes in these two key physiological markers.

Primary Regulatory Endpoints and Study Design

Clinical research primarily focused on measuring whether the medicine could lead to sustained suppression of serum testosterone to a level of le 50 ng/dL or lower. The design of these initial pivotal trials often involved observation over short-to-intermediate time intervals, such as six to twelve months. Because these studies were often non-comparative, they were designed to confirm that the medicine's profile was consistent with established hormonal benchmarks, rather than comparing it directly against other therapies or a placebo.

Long-Term Research and Durability of Response

While the initial studies monitored the short-term achievement of testosterone suppression, research has also explored the durability and sustained nature of this hormonal finding. The evidence derived from these studies includes data gathered over defined time intervals, particularly through extended observation phases that followed patients past the initial six-month period.

However, there is limited information for long-term outcomes regarding survival metrics and patient-reported quality of life over many years that were assessed in relation to the medicine. The maximum follow-up durations described in the core regulatory documentation focus on the maintenance of the hormonal biomarker, meaning that long-term data are still emerging in the initial research.

Common questions about Элигард (FAQ)

Q: Can I take this medication if I have high blood pressure or heart disease?

Official regulatory labeling advises consumers to ask a health professional before using this type of medicine if they have high blood pressure, heart disease, or have previously had a stroke. This warning is in place because Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may increase the risk of serious cardiovascular events, such as heart attack and stroke. A health professional should determine the appropriateness of this type of medication based on an individual's complete medical history.

---

Q: Does this medicine cause sleepiness or drowsiness?

Official documents list somnolence (sleepiness) or dizziness as potential side effects. Regulatory documents advise that if these effects occur, caution is warranted when performing activities requiring full mental alertness, such as driving or operating machinery.

---

Q: Is this drug safe to take during pregnancy or while breastfeeding?

Official drug information consistently advises consulting a health professional before using this medicine during pregnancy or breastfeeding. Furthermore, official labeling for NSAIDs emphasizes that use is not recommended at 20 weeks or later in pregnancy unless specifically advised by a doctor. This advice is emphasized in regulatory labeling due to concerns regarding use during late pregnancy.

---

Q: Can children under 12 years old use this product?

For adult formulations, the official regulatory directions typically advises against use in children under 12 years of age, or recommends consultation with a health professional. Dosage and administration information is provided only for individuals 12 years and older.

---

Q: Should I take this on an empty stomach or with food?

Regulatory information for many products in this class recommends taking the medication with food or milk if you experience stomach upset. This guidance is included in regulatory information to help manage the potential for gastrointestinal upset.

---

Q: Is it safe to take this for a long time (long-term use)?

Regulatory documents for over-the-counter pain relievers specify time limits for use. Regulatory documents indicate that the product should typically not be used for pain for more than 10 days, or for fever for more than 3 days, without direction from a health professional. Regulatory sources establish these time frames for use without medical oversight.

How to Store and Dispose of Eligard

Storage Conditions

The unopened Eligard kit must be stored under refrigeration between 2 C and 8 C (35.6 F and 46.4 F) and must not be frozen. The product should remain in its original packaging to protect it from light and moisture. If removed from the refrigerator, the kit is stable at room temperature (up to 30 C) for a maximum period of eight weeks. After removal, the components must be allowed to reach room temperature for approximately 30 minutes before mixing.

Stability and Disposal

Once the product is reconstituted (mixed), it must be administered immediately or be discarded within 30 minutes. The medicine must be kept out of the sight and reach of children. Used components must be disposed of in an appropriate biohazard or sharps container. Unused or expired Eligard must not be discarded in household waste or wastewater and should be returned to a pharmacist for proper disposal.